These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
39 related articles for article (PubMed ID: 8104348)
1. Initial improvement as a criterion for drug choice in acute schizophrenia. Klimke A; Klieser E; Lehmann E; Miele L Pharmacopsychiatry; 1993 Jan; 26(1):25-9. PubMed ID: 8104348 [TBL] [Abstract][Full Text] [Related]
2. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M; Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763 [TBL] [Abstract][Full Text] [Related]
3. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Haas S; Beckmann H Pharmacopsychiatria; 1982 Mar; 15(2):70-4. PubMed ID: 7043498 [TBL] [Abstract][Full Text] [Related]
4. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients]. Dieterle DM; Müller-Spahn F; Ackenheil M Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334 [TBL] [Abstract][Full Text] [Related]
5. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. den Boer JA; Westenberg HG Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547 [TBL] [Abstract][Full Text] [Related]
6. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness]. Wetzel H; von Bardeleben U; Holsboer F; Benkert O Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336 [TBL] [Abstract][Full Text] [Related]
7. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study. Meya U; Renfordt E Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296 [TBL] [Abstract][Full Text] [Related]
8. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. Lee BJ; Lee JG; Kim YH J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979 [TBL] [Abstract][Full Text] [Related]
9. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Petit M; Raniwalla J; Tweed J; Leutenegger E; Dollfus S; Kelly F Psychopharmacol Bull; 1996; 32(1):81-7. PubMed ID: 8927680 [TBL] [Abstract][Full Text] [Related]
10. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
12. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Akhondzadeh S; Safarcherati A; Amini H Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232 [TBL] [Abstract][Full Text] [Related]
13. Predictors of therapeutic response to haloperidol in acute schizophrenia. McEvoy JP; Schooler NR; Wilson WH Psychopharmacol Bull; 1991; 27(2):97-101. PubMed ID: 1924667 [TBL] [Abstract][Full Text] [Related]
14. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Chin CN; Hamid AR; Philip G; Ramlee T; Mahmud M; Zulkifli G; Loh CC; Zakariah MS; Norhamidah MS; Suraya Y; Roslan KA; Chandramohan P; Cheah YC; Leonard AO Med J Malaysia; 1998 Dec; 53(4):365-71. PubMed ID: 10971979 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients]. Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637 [No Abstract] [Full Text] [Related]
16. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. Bartkó G; Herczeg I; Békésy M J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207 [TBL] [Abstract][Full Text] [Related]
17. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702 [TBL] [Abstract][Full Text] [Related]
18. Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome. Volz HP; Mackert A; Diefenbacher A; Friedrich A; Gaebel W; Müller H; Stock G; Möller HJ Neuropsychobiology; 1994; 30(2-3):94-100. PubMed ID: 7800170 [TBL] [Abstract][Full Text] [Related]
19. Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol. Klieser E; Lehmann E Neuropsychobiology; 1987; 18(3):122-6. PubMed ID: 3453428 [TBL] [Abstract][Full Text] [Related]
20. Auditory evoked potentials in schizophrenic patients before and during neuroleptic treatment. Relationship to psychopathological state. Adler G; Gattaz WF Eur Arch Psychiatry Clin Neurosci; 1993; 242(6):357-61. PubMed ID: 8323986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]